Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
暂无分享,去创建一个
Marc C. Huisman | Otto S. Hoekstra | N. Harry Hendrikse | G. V. van Dongen | O. Hoekstra | J. Zijlstra | N. Beckmann | N. Hendrikse | S. Nimmagadda | M. Huisman | Danielle J. Vugts | Guus A. M. S. van Dongen | D. Vugts | C. W. Menke-van der Houven van Oordt | N. Harry Hendrikse | C. Willemien Menke-van der Houven van Oordt | Yvonne W. S. Jauw | Josée M. Zijlstra | Y. Jauw | A. Scott | Olivia Newton-John | Front | C. Willemien Menke-Van Der Houven Van Oordt
[1] G. Snow,et al. Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] E. D. de Vries,et al. TGF-β Antibody Uptake in Recurrent High-Grade Glioma Imaged with 89Zr-Fresolimumab PET , 2015, The Journal of Nuclear Medicine.
[3] H. Hollema,et al. VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients. , 2010, European journal of cancer.
[4] Ronald Boellaard,et al. Radiation Dosimetry of 89Zr-Labeled Chimeric Monoclonal Antibody U36 as Used for Immuno-PET in Head and Neck Cancer Patients , 2009, Journal of Nuclear Medicine.
[5] C. Swanton,et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients , 2014, Clinical Cancer Research.
[6] R. Pleijhuis,et al. 89 Zr-Bevacizumab PET Imaging in Primary Breast Cancer , 2013 .
[7] P. Lamy,et al. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. , 2012, Cancer treatment reviews.
[8] P. L. Jager,et al. Biodistribution of 89Zr‐trastuzumab and PET Imaging of HER2‐Positive Lesions in Patients With Metastatic Breast Cancer , 2010, Clinical pharmacology and therapeutics.
[9] J. Douillard,et al. Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status , 2015, Drugs.
[10] S. Larson,et al. Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.
[11] R. Boellaard,et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer , 2015, Oncotarget.
[12] S. Larson,et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. , 1991, Journal of the National Cancer Institute.
[13] G. Snow,et al. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] G. Snow,et al. Radioimmunoscintigraphy and biodistribution of technetium-99m-labeled monoclonal antibody U36 in patients with head and neck cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] E. D. de Vries,et al. Trastuzumab pharmacokinetics influenced by extent human epidermal growth factor receptor 2-positive tumor load. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial , 2016, BMC Cancer.
[17] Ira Mellman,et al. Antibody Therapeutics in Cancer , 2013, Science.
[18] C. Haioun,et al. Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010 , 2010, Leukemia & lymphoma.
[19] R. Boellaard,et al. Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer Patients , 2006, Clinical Cancer Research.
[20] H. Hollema,et al. 89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment , 2015, The Journal of Nuclear Medicine.
[21] Danny F. Martinez,et al. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer , 2015, Clinical Cancer Research.
[22] R. Hicks,et al. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[23] A. Scott,et al. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] L. Moja,et al. Trastuzumab containing regimens for early breast cancer. , 2012, The Cochrane database of systematic reviews.
[25] O. Hoekstra,et al. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment , 2015, Clinical Cancer Research.
[26] Sam S. Chang. Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.
[27] W. Oyen,et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Jason S. Lewis,et al. Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives , 2014, Molecular pharmaceutics.
[29] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. Boellaard,et al. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] E. D. de Vries,et al. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts , 2015, Oncotarget.
[32] P. Jurek,et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.
[33] Serge K. Lyashchenko,et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[34] R. Boellaard,et al. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied? , 2015, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[35] J. Reichert. Antibodies to watch in 2016 , 2016, mAbs.
[36] Roel Wierts,et al. Multicenter Harmonization of 89Zr PET/CT Performance , 2014, The Journal of Nuclear Medicine.
[37] W. Piacibello,et al. Expression of the c‐ErbB‐2/HER2 proto‐oncogene in normal hematopoietic cells , 2003, Journal of leukocyte biology.
[38] M. Lubberink,et al. Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[39] E. D. de Vries,et al. Everolimus Reduces 89Zr-Bevacizumab Tumor Uptake in Patients with Neuroendocrine Tumors , 2014, The Journal of Nuclear Medicine.
[40] J. Bergh,et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] R. Boellaard,et al. Pilot study of 89Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer , 2014, EJNMMI Research.
[42] S. Cuzzocrea,et al. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity , 2015, Oncotarget.
[43] Alexander Staab,et al. A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus , 2006, Clinical Cancer Research.
[44] R. Pleijhuis,et al. 89Zr-Bevacizumab PET Imaging in Primary Breast Cancer , 2012, The Journal of Nuclear Medicine.
[45] E. Van Cutsem,et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] James B. Evans,et al. Next-generation antibodies , 2014, Nature Reviews Drug Discovery.